Therefore, aside from some common adverse effects caused by PI3K/Akt/mTOR inhibitors, such as hyperglycemia, rash, asthenia and mucositis, there are other chronic adverse effects that might develop over a longer term and that might not be detected in initial clinical trials. Here, MTOR is linked to Hyperglycemia.